Actinogen Medical Ltd
ASX:ACW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Actinogen Medical Ltd
Operating Income
Actinogen Medical Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Actinogen Medical Ltd
ASX:ACW
|
Operating Income
-AU$17.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-10%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$73.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Operating Income
-AU$8.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$30.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$46.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
|
Actinogen Medical Ltd
Glance View
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.
See Also
What is Actinogen Medical Ltd's Operating Income?
Operating Income
-17.7m
AUD
Based on the financial report for Dec 31, 2025, Actinogen Medical Ltd's Operating Income amounts to -17.7m AUD.
What is Actinogen Medical Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-10%
Over the last year, the Operating Income growth was -86%. The average annual Operating Income growth rates for Actinogen Medical Ltd have been -17% over the past three years , -37% over the past five years , and -10% over the past ten years .
